Research
Energy balance
There is a general recommendation against the use of non–FDA‐approved compounded incretin analogs.
Clinicians should be cautious and consider FDA approval status when prescribing incretin analogs.
StrongSupportsmedium confidence
While there is a general recommendation against the use of non–FDA‐approved compounded incretin analogs.
Why this rating
The abstract discusses established recommendations.
Source
Legal, safety, and practical considerations of compounded injectable semaglutide
Allison Spitery et al. · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · 2024
DOI 10.1002/jac5.1999
reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The use of long‐acting incretin‐based therapies, such as semaglutide, has increased due to their benefits for glycemic control in diabetes, cardiovascular risk reduction, and weight management.Strong
- If clinicians elect to use compounded incretin‐based therapy, they must consider the potential harms and benefits for each patient.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →